Two years ago, the Parsemus Foundation partnered with NEXT Life Sciences to prepare Vasalgel — the non-hormonal, long-lasting, and reversible male contraceptive — for human
A first-of-its-kind hormone-free birth control pill for men shows promise in a clinical trial. Here’s news about YCT-529, a drug you may hear more about
The Male Contraceptive Initiative celebrates its 10-year anniversary this year! The U.S.-based nonprofit organization is a leading funder and advocate for male contraception. Their stated
NEXT Life Sciences announced that world-renowned vasectomy doctors have joined its medical advisory board, marking significant progress toward making a long-lasting, non-hormonal, reversible contraceptive available
The promise of new male contraceptive options was highlighted in an article by Kelcie Moseley-Morris published in News from the States. Heather Vahdat of the
The Parsemus Foundation founder and trustee, Elaine Lissner, was invited to speak about male contraception at the SXSW event on March 10, 2023. SXSW (“south
NEXT Life Sciences, Inc. announced on March 22, 2023 its plans for the Plan A™ male contraceptive. Vasalgel, the polymer hydrogel developed by the Parsemus
The Male Contraceptive Initiative Youth Advisory Board is offering a grant to undergraduate students for research on male contraception. Undergraduate students anywhere in the world
The Parsemus Foundation and Revolution Contraceptives LLC are pleased to announce that NEXT Life Sciences, Inc. has been selected to continue development of the Vasalgel
The Male Contraceptive Initiative’s Youth Advisory Board recently selected four undergraduate students for awards to fund research in male contraception. The Parsemus Foundation is proud
And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:
